Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Anti-CTLA4 therapy has not been comprehensively explored for the treatment of metastatic renal cell carcinoma (mRCC). Here, in a pilot study of anti-CTLA4 therapy with or without cryoablation in mRCC, the authors report that the combination is feasible and enhances immune infiltration in patients wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Matthew T. Campbell, Surena F. Matin, Alda L. Tam, Rahul A. Sheth, Kamran Ahrar, Rebecca S. Tidwell, Priya Rao, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Eric Jonasch, Jianjun Gao, Amado J. Zurita, Amishi Y. Shah, Sonali Jindal, Fei Duan, Sreyashi Basu, Hong Chen, Alexsandra B. Espejo, James P. Allison, Shalini S. Yadav, Padmanee Sharma
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/204efb116032411484ebc80c52f409dc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Anti-CTLA4 therapy has not been comprehensively explored for the treatment of metastatic renal cell carcinoma (mRCC). Here, in a pilot study of anti-CTLA4 therapy with or without cryoablation in mRCC, the authors report that the combination is feasible and enhances immune infiltration in patients with metastatic clear cell histology.

Ejemplares similares